In the Driver’s Seat With EGFR: Application of Mutation Testing to Treatment Selection for NSCLC
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches.
This series offers two interactive programs supported by audio and video commentary, where expert faculty share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:
• Increase implementation of best practices for EGFR mutation testing in patients with NSCLC
• Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC
• Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC
Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC
Interactive Practice GuideThis interactive digital activity combines animated slides and expert video commentary on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence to enhance the implementation of precision medicine in the care of patients with EGFR-mutant NSCLC. Through this education, learners explore best practices for EGFR mutation testing, application of clinical trial data to treatment selection, and the role of concurrent mutations in the prognosis and response to therapy of patients with EGFR-mutant NSCLC.
Faculty: Maria Arcila, MD; Justin Gainor, MD
Release Date:
Expiration Date: December 30, 2022
CME/CE is no longer available for this activity
Case Challenges in Patients With EGFR-Mutant NSCLC
Case-based EducationThis activity offers a case challenge of two patients with EGFR-mutant NSCLC, through which learners apply knowledge from the molecular testing guidelines and evidence from clinical trials as presented in the related activity, Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC. Learners work through patient cases during which they are questioned about how they would proceed at different clinical decision points. Expert clinical commentary includes recommendations and evidence for next steps.
Faculty: Justin Gainor, MD
Release Date:
Expiration Date: December 30, 2022
CME/CE is no longer available for this activity
